Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 49 Lung Neoplasms 12 Neoplasms 3 Adenocarcinoma 3 Carcinoma, Squamous Cell 2 ALK-positive NSCLC 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 2a 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma 1 Hematologic Neoplasms 1 Granuloma, Plasma Cell 1 Glioma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Large Cell 1

Interventions

Docetaxel 8 pembrolizumab 7 Pemetrexed 5 Carboplatin 5 Erlotinib Hydrochloride 4 toripalimab 3 rociletinib 3 fludarabine 3 Radiosurgery 3 Paclitaxel 3 Oxaliplatin 3 Nivolumab 3 Gemcitabine 3 Etoposide 3 Cyclophosphamide 3 Cisplatin 3 Bevacizumab 3 lorlatinib 2 atezolizumab 2 Vinorelbine 2 Topotecan 2 Radiotherapy 2 Platinum 2 Itraconazole 2 Irinotecan 2 Interleukin-2 2 Cetuximab 2 Albumin-Bound Paclitaxel 2 vinflunine 1 vandetanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Crizotinib × Thoracic × Clear all

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡